Pleads guilty Dec. 6 in Baltimore federal court to 10 criminal violations related to the company's falsification of ANDA applications in 1986-87, its use of unapproved ingredients or deviations from approved ANDA manufacturing methods and the obstruction of an FDA inspection. Par received a $ 2.5 mil. criminal fine. Par parent Pharmaceutical Resources had said on Nov. 21 that the company would plead guilty ("The Pink Sheet" Nov. 25, T&G-15).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth